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Associations of wheezing phenotypes with late asthma outcomes in ALSPAC: a population-based 
birth cohort  
Raquel Granell*, Jonathan A.C. Sterne & John Henderson 
 
Online Data Supplement 
Participants 1 
ALSPAC recruited 14,541 pregnant women resident in Avon, UK with expected dates of delivery 2 
1st April 1991 to 31st December 1992. 14,541 is the initial number of pregnancies for which the 3 
mother enrolled in the ALSPAC study and had either returned at least one questionnaire or 4 
attended a “Children in Focus” clinic by 19/07/99. Of these initial pregnancies, there was a total of 5 
14,676 fetuses, resulting in 14,062 live births and 13,988 children who were alive at 1 year of age. 6 
When the oldest children were approximately 7 years of age, an attempt was made to bolster the 7 
initial sample with eligible cases who had failed to join the study originally. As a result, when 8 
considering variables collected from the age of seven onwards (and potentially abstracted from 9 
obstetric notes) there are data available for more than the 14,541 pregnancies mentioned above. 10 
The number of new pregnancies not in the initial sample (known as Phase I enrolment) that are 11 
currently represented on the built files and reflecting enrolment status at the age of 18 is 706 (452 12 
and 254 recruited during Phases II and III respectively), resulting in an additional 713 children 13 
being enrolled. The phases of enrolment are described in more detail in the cohort profile paper1. 14 
The total sample size for analyses using any data collected after the age of seven is therefore 15 
15,247 pregnancies, resulting in 15,458 fetuses. Of this total sample of 15,458 fetuses, 14,775 16 
were live births and 14,701 were alive at 1 year of age. 17 
 A 10% sample of the ALSPAC cohort, known as the Children in Focus (CiF) group, attended 18 
clinics at the University of Bristol at various time intervals between 4 to 61 months of age. The 19 
CiF group were chosen at random from the last 6 months of ALSPAC births (1432 families 20 
attended at least one clinic). Excluded were those mothers who had moved out of the area or were 21 
lost to follow-up, and those partaking in another study of infant development in Avon. 22 
Please note that the study website contains details of all the data that is available through a fully 23 
searchable data dictionary" and reference the following webpage: 24 
<http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/> 25 
Skin Prick Test 26 
Atopy was measured at a research clinic at age 7½ years, as previously described (1). A positive 27 
response was defined as a mean weal diameter of >2 mm with an absent response to negative 28 
control solution, and atopy was defined as a positive response to one or more of house dust mite, 29 
cat or grass pollen. 30 
FeNO at 14-15 years 31 
Fractional exhaled nitric oxide (FeNO) was measured online at a constant flow of 50mL/s 32 
according to European Respiratory Society (ERS) and American Thoracic Society (ATS) 33 
guidelines using a Sievers NOA-280i nitric oxide analyser (GE Analytical Instruments, Boulder, 34 
CO.).  35 
Additionally, 758 children with less stringent criteria (individual blows >5% deviation but at least 36 
1 within acceptable rang of 10-200 ppb) were included. FeNO measurements were done before 37 
spirometry measurements. Children were requested to omit their inhaled corticosteroids if 38 
applicable 48 hours before their visit to the clinic. At the time of measurements, 14 children 39 
(0.3%) received oral steroids, 221 (5.2%) had a chest infection and/or fever with a cold in the 40 
preceding three weeks, and 39 (0.9%) and 89 (2.1%) had used short acting or long acting 41 
bronchodilators 6 or 24 hours, respectively, prior to the respiratory assessments. These children, 42 
and those with less stringent criteria of FeNO values, were included in our analyses since we 43 
observed no differences in results when they were included or excluded.  44 
Asthma status 0 to 14 years 45 
Using ever-reported doctor-diagnosed asthma at 91 and 166 months and maternal report of asthma 46 
at 166 months , we derived the following asthma status variable: “no asthma" if negative at both 47 
91 and 166 months, “remittent asthma” if positive at 91 months but negative at 166 months or 48 
positive at both 91 and 166 months but negative maternal report of asthma in the last 12 months at 49 
166 months , “incident asthma” if negative at 91 months but positive at 166 months and 50 
“persistent asthma” if positive at both 91 and 166 months and  positive maternal report of asthma 51 
in the last 12 months at 166 months. 52 
Potential Confounders 53 
We obtained details of maternal educational attainment (lower level defined as educated to school 54 
leaving certificate at 16 years or lower), smoking history and personal history of asthma or allergy 55 
from questionnaires sent to the mother during pregnancy . Sex of the child was obtained from 56 
delivery health care records. Postnatal maternal questionnaires from 3-15 months after birth were 57 
used to ascertain environmental tobacco smoke exposure. 58 
 59 
Statistical analysis 60 
In order to minimise the risk of bias due to misclassification, associations of wheezing phenotypes 61 
with late asthma outcomes (physician-diagnosed asthma and objective measurements of lung 62 
function and FeNO) were examined using logistic or linear regression models weighted for the 63 
probability of each individual of belonging to each phenotype. These probabilities were estimated 64 
previously and referred to as the posterior probabilities (2). Crude and adjusted odds ratios (for 65 
binary outcomes) and mean differences (for continuous outcomes) were derived in relation to the 66 
never/infrequent wheezing phenotype (reference group). Adjustment was done for potential 67 
confounders (gender, maternal lower education level, having at least one sibling (parity), maternal 68 
history of asthma or allergy, maternal smoking during pregnancy, maternal anxiety during 69 
pregnancy (as being in the 4th quantile of the Crown-Crisp Experiential Index (3)), low birth 70 
weight (<2.5kg), preterm delivery (<37 weeks) and daycare attendance during the first year. 71 
Table E1 72 
A total of 6330 (51.5%) participants were males, 5139 (46.2%) had an asthmatic or allergic 73 
mother, 2934 (26.1%) were exposed to maternal smoking during pregnancy and 6148 (54.9%) had 74 
at least one sibling. 575 (5.0%) had low birth weight and 682 (5.8%) were born preterm. 2529 75 
(23.4%) were exposed to maternal smoking during the first year and 641 (6.0%) attended day care 76 
during the first year. 2874 (26.1%) participants had wheezing reported at 6 months: the proportion 77 
of participants with reported wheezing decreased to 1756 (17.6%) by 3½ years, 1050 (12.9%) by 78 
8½ years and 592 (10.5%) by 16½ years. Of 6691 participants with data available on skin prick 79 
tests at 7½ years, 1403 (21.0%) were atopic. 80 
Comparing the samples of children with complete (n=3,170) and incomplete data (at least 2 81 
observations of wheeze, n=9,133) on wheezing, we observed that incomplete data are associated 82 
with markers of social deprivation: increased exposure to tobacco smoke (p=), maternal anxiety 83 
(p=), maternal lower education (p=), parity (p=), low birthweight (p=) and pre-term delivery (p=), 84 
in those subsequently lost to follow up. Also, the proportion of wheezing differs between 6 and 69 85 
months (p<)  but its similar thereafter which is consistent with less wheezing reported among 86 
children with complete data, compared to those subsequently lost to follow up. Our analyses 87 
included children with incomplete data on wheeze, avoiding bias that could be introduced in 88 
complete case analyses. 89 
Table E2 90 
Male gender (adjusted multinomial odds ratios [mOR] range from 1.32 to 1.80) was associated 91 
with a similar higher risk of each phenotype (heterogeneity p-value=0.13). Maternal lower 92 
education level was associated with a higher risk of mid-childhood onset remitting wheeze (mOR 93 
1.22, 1.02 to 1.45 with little evidence of heterogeneity p-value=0.11). Having at least one sibling 94 
was associated with pre-school and mid-childhood onset remitting and continuous wheezing 95 
phenotypes and there was little evidence for association with the other phenotypes (heterogeneity 96 
p-value=0.0012). Maternal history of asthma or allergy was associated with a higher risk of each 97 
wheezing phenotype (mOR 1.27 to 2.30, heterogeneity p-value<0.0001), strongest associations 98 
were with mid-childhood onset remitting (mOR 1.65 95%CI 1.40 to 1.93) and continuous 99 
wheezing (mOR 2.30 95%CI 1.88 to 2.81). Maternal smoking during pregnancy was associated 100 
with a higher risk of pre-school and mid-childhood onset remitting and continous wheeze 101 
phenotypes (mOR 1.33 to 1.46, heterogeneity p-value=0.71). Prenatal maternal anxiety was 102 
associated with a higher risk of each wheezing phenotype (mOR 1.12 to 1.29, heterogeneity p-103 
value=0.08). Low birth weight was associated with continuous wheeze (mOR 1.63 95%CI 1.00 to 104 
2.64, heterogeneity p-value=0.26). Preterm delivery was associated with higher risk of pre-school 105 
and mid-childhood onset remitting and continuous wheezing (mOR 1.35 to 1.63, heterogeneity p-106 
value=0.30).Day care attendance during the first year was associated with a higher risk of pre-107 
school onset remitting wheeze phenotype, although we found small evidence of heterogeneity p-108 
value=0.16. We found small evidence for an association between maternal smoking during the 109 
first year and any of the wheezing phenotypes. 110 
 111 
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Table E1 Characteristics of children with at least 2 observations of wheeze (study population, 121 
N=12,303) who did and did not have complete data on wheezing. 122 
 
Children with complete 
data on wheezing 
(n1=3,170) 
Children with 2–13 
observations of wheezing 
(n2=9,133) 
Two-sample test of 
proportions 
 n/total % n/total % P-value 
Potential confounders      
Gender (Male) 1560/3170 49.2 4770/9133 52.2 0.003 
Lower maternal education* 1547/3151 49.1 5614/8184 68.6 <0.0001 
Having at least 1 sibling (parity) 1597/3118 51.2 4551/8072 56.4 <0.0001 
Maternal history of asthma or allergy 1510/3107 48.6 3629/8025 45.2 0.001 
Maternal smoking during pregnancy 439/3127 14.0 2495/8096 30.8 <0.0001 
Maternal anxiety during pregnancy† 479/3020 15.9 1831/7520 24.3 <0.0001 
Low birth weight (<2.5Kg) 134/3134 4.3 441/8397 5.3 0.032 
Preterm delivery (<37 weeks) 153/3170 4.8 529/8504 6.2 0.004 
Maternal smoking during first year 411/3122 13.2 2118/7690 27.5 <0.0001 
Day care attendance during 1st year 242/3124 7.7 399/7505 5.3 <0.0001 
Variables used in the Latent Class model      
Reported wheezing at      
6 months 709/3170 22.4 2165/7834 27.6 <0.0001 
18 months 780/3170 24.6 2205/7691 28.7 <0.0001 
30 months 612/3170 19.3 1632/6775 24.1 <0.0001 
42 months (3½ years) 487/3170 15.4 1269/6803 18.7 <0.0001 
54 months 505/3170 15.9 1269/6221 20.4 <0.0001 
69 months 435/3170 13.7 893/5426 16.5 .0007 
81 months 393/3170 12.4 734/5225 14.0 0.70 
91 months 334/3170 10.5 544/5032 10.8 0.14 
103 months (8½ years) 386/3170 12.2 664/4990 13.3 0.41 
128 months 376/3170 11.9 559/4475 12.5 0.37 
140 months 360/3170 11.4 509/4229 12.0 0.83 
157 months 338/3170 10.7 402/3828 10.5 0.44 
166 months 339/3170 10.7 424/3760 11.3 0.86 
198 months (16½ years) 335/3170 10.6 257/2465 10.4 0.39 
 Atopy at 7½ years (skin prick testing) 524/2433 21.5 879/4258 20.6 0.70 
*Educated to GCE level (school leaving certificate) or lower 123 
† Defined as being in the 4th quantile of the Crown-Crisp Experiential Index 124 
 125 
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Table E2 Associations of possible confounders with wheezing phenotypes 0 to 16½ years and asthma at 14 years (Based on 12,303 children with at 
least 2 observations of wheezing)  
 Adjusted Multinomial OR (95% CI) for  
 
Pre-school onset 
remitting* 
N=1,605 
Mid-childhood 
onset remitting* 
N=620 
School-age onset 
persisting* 
N=346 
Late-childhood 
onset  persisting* 
N=324 
Continuous 
wheeze* 
N=420 
Heteroge
neity p-
value+ 
Adjusted OR (95% 
CI) for Doctor ever 
diagnosed-asthma at 
14 years 
N=5,838 
Demographic, maternal, pregnancy & child characteristics (adjusted by each other)  
Gender (Male) 1.39 (1.25, 1.55) 1.41 (1.21, 1.66) 1.54 (1.26, 1.89) 1.32 (1.09, 1.60) 1.80 (1.48, 2.19) 0.13 1.26 (1.11,1.42) 
Maternal lower education level ± 0.96 (0.86, 1.08) 1.22 (1.02, 1.45) 0.92 (0.74, 1.13) 0.94 (0.77, 1.14) 0.95 (0.77, 1.16) 0.11 1.13 (1.00,1.28) 
Parity 1.24 (1.11, 1.38) 1.38 (1.17, 1.62) 0.88 (0.72, 1.07) 1.02 (0.85, 1.24) 1.37 (1.12, 1.67) 1.2E-03 0.95 (0.84,1.07) 
Maternal history of asthma or allergy 1.27 (1.14, 1.42) 1.65 (1.40, 1.93) 1.47 (1.20, 1.80) 1.42 (1.17, 1.72) 2.30 (1.88, 2.81) 1.9E-06 1.53 (1.35,1.73) 
Maternal smoking during pregnancy 1.33 (1.17, 1.51) 1.46 (1.22, 1.75) 1.23 (0.97, 1.56) 1.24 (0.99, 1.56) 1.38 (1.10, 1.72) 0.71 1.19 (1.01,1.39) 
Maternal anxiety during pregnancy 1.20 (1.14, 1.26) 1.25 (1.16, 1.35) 1.12 (1.02, 1.23) 1.14 (1.04, 1.24) 1.29 (1.18, 1.41) 0.08 1.13 (1.07,1.20) 
Perinatal characteristics adjusted by demographic, maternal, pregnancy and child characteristics  
Low birthweight (<2.5Kg) ‡ 1.00 (0.73, 1.37) 1.14 (0.73, 1.78) 1.47 (0.86, 2.52) 1.56 (0.93, 2.60) 1.63 (1.00, 2.64) 0.26 1.11 (0.77,1.61) 
Preterm delivery (<37 weeks) ‡ 1.35 (1.07, 1.70) 1.43 (1.03, 2.00) 1.04 (0.65, 1.67) 0.94 (0.59, 1.50) 1.63 (1.11, 2.39) 0.30 1.16 (0.87,1.56) 
Postnatal characteristics adjusted by demographic, maternal, pregnancy, child, perinatal & other postnatal characteristics  
Maternal smoking during first year 1.22 (0.98, 1.51) 1.15 (0.84, 1.58) 0.96 (0.64, 1.44) 1.01 (0.69, 1.49) 1.09 (0.74, 1.61) 0.80 1.06 (0.82,1.37) 
Day care attendance during 1st year 1.28 (1.02, 1.60) 0.97 (0.66, 1.41) 0.72 (0.44, 1.18) 0.92 (0.59, 1.42) 1.07 (0.70, 1.63) 0.16 0.90 (0.70,1.17) 
* compared with never/infrequent wheezing (N=6,305) and using each child’s phenotype probability as weights. 
± Educated to school leaving certificate at 16 years (GCE level) or lower 
+ Chi-squared test across phenotypes 
‡ Low birthweight was also adjusted by preterm delivery but preterm delivery was not adjusted for low birth weight (since birth weight does not influence gestational age) 
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Table E3 Crude associations of wheezing phenotypes 0 to 16½ years with doctor-diagnosed asthma ever, FeNO and BDR>12% at 14-15 years 
(based on in 12,303 children with at least 2 observations of wheeze) 
 Doctor-diagnosed asthma ever at 14 years FeNO ≥35 ppb at 14-15 years BDR >12% at 15 years 
Wheezing phenotype 0 to 16½ years 
Number of 
asthmatic/total* 
OR (95% CI)  n1/total* OR (95% CI) n2/total* OR (95% CI)  
Never/Infrequent 272/3661 1 (ref) 290/1157 1 (ref) 139/2003 1 (ref) 
Pre-school onset remitting 173/ 870 2.74 (2.23, 3.36) 61/ 243 1.06 (0.79, 1.44) 33/ 472 1.10 (0.76, 1.59) 
Mid-childhood onset remitting 231/ 337 25.0 (19.4, 32.2) 42/ 102 1.93 (1.28, 2.90) 21/ 204 1.66 (1.04, 2.63) 
School-age onset persisting 187/ 223 49.9 (35.3, 70.7) 57/  82 6.39 (3.95, 10.34) 27/ 127 3.28 (2.06, 5.22) 
Late-childhood onset persisting 161/ 250 19.8 (15.0, 26.1) 38/  66 3.67 (2.30, 5.85) 19/ 131 2.10 (1.26, 3.48) 
Continuous wheeze 246/ 254 363 (179, 735) 49/  71 6.95 (4.13, 11.72) 19/ 126 2.36 (1.40, 3.98) 
* Number of children with data available (approximated from modal assignment) 
n1: Number of children with FeNO ≥20 ppb 
n2: Number of children with BDR>12% 
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Table E4 Crude association of wheezing phenotypes 0 to 16½ years with lung function measures at 15 years (z-scores) based on 12,303 children 
with at least to observations of wheezing 
 FEV1 (SDU) at 15 years FVC (SDU) at 15 years FEV1/FVC (SDU) at 15 years FEF25-75 (SDU) at 15 years 
Wheezing phenotype 0 to 16½ years N Mean diff. (95% CI)  N Mean diff. (95% CI)  N Mean diff. (95% CI)  N Mean diff (95% CI)  
Never/Infrequent 1997 0 (ref) 2094 0 (ref) 1997 0 (ref) 2094 0 (ref) 
Pre-school onset remitting 463 -0.02 (-0.12, 0.07) 477 0.05 (-0.04, 0.14) 463 -0.15 (-0.24, -0.05) 477 -0.13 (-0.22, -0.03) 
Mid-childhood onset remitting 203 0.09 (-0.05, 0.23) 209 0.21 (0.07, 0.35) 203 -0.23 (-0.37, -0.08) 209 -0.14 (-0.28, -0.00) 
School-age onset persisting 127 0.08 (-0.10, 0.26) 131 0.18 (0.00, 0.35) 127 -0.21 (-0.39, -0.04) 131 -0.14 (-0.32, 0.03) 
Late-childhood onset persisting 130 -0.02 (-0.19, 0.15) 135 0.02 (-0.14, 0.19) 130 -0.08 (-0.25, 0.08) 135 -0.21 (-0.37, -0.04) 
Continuous wheeze 126 -0.08 (-0.26, 0.10) 131 0.04 (-0.14, 0.22) 126 -0.26 (-0.44, -0.08) 131 -0.30 (-0.48, -0.12) 
N: Number of children with data available (approximated from modal assignment) 
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Table E5 Adjusted associations of wheezing phenotypes 0 to 16½ years with lung function measures at 8 years (z-scores), in participants with at 
least 2 observations of wheeze. 
 FEV1 (SDU) at 8 years FVC (SDU) at 8 years FEV1/FVC (SDU) at 8 years FEF25-75 (SDU) at 8 years 
Wheezing phenotype 0 to 16½ years 
N 
Adjusted Mean diff. 
(95% CI) * 
N 
Adjusted Mean diff. 
(95% CI) * 
N 
Adjusted Mean 
diff. (95% CI) * 
N 
Adjusted Mean diff 
(95% CI) * 
Never/Infrequent 3394 0 (ref) 3452 0 (ref) 3295 0 (ref) 3452 0 (ref) 
Pre-school onset remitting 872 -0.20 (-0.28, -0.13) 884 -0.06 (-0.13, 0.02) 851 -0.24 (-0.31, -0.17) 884 -0.28 (-0.35, -0.21) 
Mid-childhood onset remitting 336 -0.23 (-0.34, -0.12) 341 -0.01 (-0.11, 0.10) 329 -0.37 (-0.48, -0.26) 341 -0.41 (-0.51, -0.30) 
School-age onset persisting 219 -0.30 (-0.43, -0.16) 222 -0.01 (-0.14, 0.12) 215 -0.44 (-0.58, -0.31) 222 -0.48 (-0.62, -0.35) 
Late-childhood onset persisting 212 -0.23 (-0.36, -0.11) 215 -0.08 (-0.21, 0.05) 207 -0.21 (-0.34, -0.08) 215 -0.30 (-0.43, -0.18) 
Continuous wheeze 245 -0.40 (-0.53, -0.27) 249 0.10 (-0.03, 0.23) 236 -0.78 (-0.91, -0.65) 249 -0.75 (-0.88, -0.62) 
* Adjusted for gender, parity, maternal history of asthma or allergy, maternal smoking and anxiety during pregnancy, preterm delivery, low birth weight and daycare attendance 
during first year. 
N: Number of participants with data available (approximated from modal assignment) 
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Table E6 Adjusted associations of wheezing phenotypes 0 to 16½ years with pre-salbutamol lung function measures at 15 years (z-scores), in 
participants with at least 2 observations of wheeze. 
 FEV1 (SDU) at 15 years FVC (SDU) at 15 years FEV1/FVC (SDU) at 15 years FEF25-75 (SDU) at 15 years 
Wheezing phenotype 0 to 16½ years N 
Adjusted Mean diff. 
(95% CI) * 
N 
Adjusted Mean diff. 
(95% CI) * 
N 
Adjusted Mean diff. 
(95% CI) * 
N 
Adjusted Mean diff 
(95% CI) * 
Never/Infrequent  2064 0 (ref) 2092 0 (ref)  2064 0 (ref)  2091 0 (ref) 
Pre-school onset remitting   473 -0.06 (-0.16, 0.03)   477 0.05 (-0.05, 0.14)   473 -0.21 (-0.31, -0.12)   476 -0.16 (-0.25, -0.06) 
Mid-childhood onset remitting   207 -0.03 (-0.17, 0.11)   209 0.16 (0.02, 0.30)   207 -0.35 (-0.49, -0.22)   209 -0.25 (-0.39, -0.11) 
School-age onset persisting   129 -0.16 (-0.33, 0.02)   131 0.08 (-0.10, 0.25)   129 -0.45 (-0.62, -0.28)   131 -0.40 (-0.57, -0.22) 
Late-childhood onset persisting   135 -0.20 (-0.36, -0.03)   135 -0.04 (-0.21, 0.13)   135 -0.29 (-0.45, -0.13)   135 -0.33 (-0.50, -0.17) 
Continuous wheeze   128 -0.23 (-0.41, -0.04)   130 0.04 (-0.14, 0.22)   128 -0.54 (-0.72, -0.37)   130 -0.53 (-0.71, -0.35) 
* Adjusted for gender, parity, maternal history of asthma or allergy, maternal smoking and anxiety during pregnancy, preterm delivery, low birth weight and daycare attendance 
during first year. 
N: Number of participants with data available (approximated from modal assignment) 
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Table E7 Adjusted associations of wheezing phenotypes 0 to 16½ years with lung function measures at 15 years (pre-salbutamol z-scores) 
further adjusted by lung function measures at 8 years (pre-salbutamol z-scores), in participants with at least 2 observations of wheeze. 
 FEV1 (SDU) at 15 years FVC (SDU) at 15 years FEV1/FVC (SDU) at 15 years FEF25-75 (SDU) at 15 years 
Wheezing phenotype 0 to 16½ years N 
Adjusted Mean diff. 
(95% CI) * 
N 
Adjusted Mean diff. 
(95% CI) * 
N 
Adjusted Mean diff. 
(95% CI) * 
N 
Adjusted Mean diff 
(95% CI) * 
Never/Infrequent 1784 0 (ref) 1826 0 (ref) 1743 0 (ref) 1825 0 (ref) 
Pre-school onset remitting 415 0.02 (-0.08, 0.11) 422 0.08 (-0.01, 0.17) 407 -0.16 (-0.25, -0.07) 421 -0.03 (-0.12, 0.06) 
Mid-childhood onset remitting 183 0.08 (-0.05, 0.22) 187 0.17 (0.04, 0.31) 179 -0.22 (-0.36, -0.09) 187 -0.02 (-0.15, 0.11) 
School-age onset persisting 110 -0.05 (-0.22, 0.13) 113 0.11 (-0.06, 0.28) 110 -0.33 (-0.50, -0.16) 113 -0.19 (-0.36, -0.03) 
Late-childhood onset persisting 117 -0.07 (-0.24, 0.09) 118 0.02 (-0.14, 0.18) 117 -0.21 (-0.37, -0.05) 118 -0.17 (-0.32, -0.01) 
Continuous wheeze 106 -0.04 (-0.22, 0.14) 110 0.06 (-0.12, 0.23) 103 -0.25 (-0.42, -0.07) 110 -0.14 (-0.31, 0.03) 
* Adjusted for gender, parity, maternal history of asthma or allergy, maternal smoking and anxiety during pregnancy, preterm delivery, low birth weight, daycare attendance 
during first year and additionally for lung function at 8 years. 
N: Number of participants with data available (approximated from modal assignment) 
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Figure E1 Distribution of 12,303 children with 2 to 14 (complete data) observations of wheeze 
 
 
Figure E2 Estimated prevalence of wheezing at each time point from birth to 16½ years for each of the six 
wheezing phenotypes identified by latent class analysis in 12,303 children with at least 2 observations of 
wheeze including atopic status as a covariate in the model. 
 
